Besilesomab
Scintimun (besilesomab) is an antibody pharmaceutical. Besilesomab was first approved as Scintimun on 2010-01-11. It has been approved in Europe to treat osteomyelitis and radionuclide imaging.
Trade Name | Scintimun |
---|---|
Common Name | Besilesomab |
Indication | osteomyelitis, radionuclide imaging |
Drug Class | Monoclonal antibodies: infix for inflammatory/infectious lesions|monoclonal antibodies: mouse, bone target |
